Tissue and repair: what the research shows
Compounds studied for wound, tendon, muscle and gut repair. This guide covers 2 of them. For each one: what is established in people, the key studies, and its status.
From our publisherAMINOSWORK, the research peptide supplier behind Peptide Guardian, posts its third-party lab reports by lot number. Open the lab report library
BPC-157
Early human trialsBPC-157 is a lab-made chain of 15 amino acids that has helped injured tissue heal in many rat studies, but the human evidence is limited to a few small, short studies and it is not an approved medicine anywhere.
Very little is established in people. The FDA counted five small human studies in 2026: an enema study in 32 healthy men, a two-week enema trial in 53 people with ulcerative colitis that did not show a clear benefit and was reported only as a conference abstract, and three uncontrolled reports from private clinics in Florida covering 17 people with knee pain, 12 women with a bladder pain condition, and 2 people given an infusion. None tested the tendon, ligament or muscle uses that BPC-157 is best known for. A placebo-controlled trial in 120 people with hamstring strains was registered in China in 2026 and a 30-person trial after shoulder surgery was registered in the United States for 2027, but neither has reported results; a 40-person open-label trial of a BPC-157 gummy finished in 2025 with no results posted.
Key studies
- Human trial, 2026. The trial was listed as recruiting, with a start date of 2 February 2026. Source: clinicaltrials.gov
- Human trial, 2025. Blood tests for the heart, liver, kidneys, thyroid and blood sugar did not change in a measurable way, and neither person reported side effects. Source: pubmed.ncbi.nlm.nih.gov
- Human trial, 2021. By the paper's own summary, 11 of the 12 people who had BPC-157 alone said their knee pain improved significantly, and 14 of 16 overall reported relief. Source: pubmed.ncbi.nlm.nih.gov
- FDA status
- Not approved. Not on the pharmacy compounding list. Named in a draft federal policy (30 October 2026) that is not an approval.
- In sport
- Prohibited at all times; named in class S0 (non-approved substances), 2026 and 2027.
TB-500 (thymosin beta-4)
Animal and cell studies onlyTB-500 is a trade name, most often for a 7-amino-acid piece of the natural protein thymosin beta-4; the full protein has been tested in people as eye drops and skin gels with mixed results, while the short piece sold as TB-500 has no published human studies.
No published human trial of the TB-500 fragment was found, and FDA's May 2026 review reported finding no study in which it had been given to people. One trial of the fragment is listed on ClinicalTrials.gov (NCT07487363, first posted March 2026, 80 participants planned, one site in China) with no results; its record contains unusual wording and should be treated with caution. Full-length thymosin beta-4 has been tested in people: two small safety studies of injections in healthy volunteers (40 and 84 people, up to 14 days), three phase 2 skin-gel trials in which healing rates were no better than placebo, and eye-drop trials in which the largest dry-eye studies (601 and 700 people) showed near-identical results for drug and placebo and a small phase 3 corneal-healing trial (18 people) showed a non-significant trend. A 2025 randomised, placebo-controlled trial of full-length thymosin beta-4 in 96 heart-attack patients found no overall difference in the area of dead heart muscle at 90 days; a smaller area in the 43 patients first treated within 8 hours is a subgroup result that needs confirming. No thymosin beta-4 product has been approved, and nothing in people supports the tendon, muscle or joint claims made for TB-500.
Key studies
- Human trial, 2025. In mice, a week of treatment after a heart attack prevented loss of heart function and scarring at 28 days, and lowered a blood marker of heart strain. Source: pubmed.ncbi.nlm.nih.gov
- Human trial, 2022. Complete healing at 4 weeks occurred in 6 of 10 patients on RGN-259 and 1 of 8 on placebo (p = 0.0656, which did not reach the usual threshold for statistical significance). Source: pubmed.ncbi.nlm.nih.gov
- Human trial, 2020. On the two main goals, the posted results were almost identical between groups. Source: clinicaltrials.gov
- FDA status
- Not approved. Not on the pharmacy compounding list.
- In sport
- Prohibited at all times; named in S2.3 (growth factors), 2026 and 2027.
Before you trust any seller
A study tells you about the compound. It tells you nothing about what is in a particular vial. How to read a lab report
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.